Use of infliximab in the treatment of Crohn's disease in children and adolescents

Crohn's disease is often poorly responsive to conventional therapy with corticosteroids and immunomodulators. A novel chimeric antibody to tumor necrosis factor-alpha, infliximab, has shown utility in the treatment of refractory Crohn's disease in adults.To evaluate the efficacy of open-label administration of infliximab in children and adolescents with active intestinal Crohn's disease.Chart review of the experience with 19 subjects (mean age...